S14 Ep23: Early Biomarker Testing Optimizes Tepotinib Use in NSCLC With MET Exon 14 Skipping Mutations: With Stephen Liu, MD
Update: 2025-10-01
Description
In today’s episode, we had the pleasure of speaking with Stephen Liu, MD, about the use of tepotinib (Tepmetko) in patients with metastatic non–small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. Dr Liu is an associate professor of medicine at Georgetown University, as well as the director of Thoracic Oncology and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC.
In our exclusive interview, Dr Liu discussed key efficacy and safety findings from the phase 2 VISION trial (NCT02864992) that led to the FDA approval of tepotinib for this indication; the comparable response rates seen between tissue and liquid biopsy results, as well as across NSCLC treatment lines; and the importance of early biomarker testing, including RNA sequencing, to identify actionable mutations and optimize treatment.
In our exclusive interview, Dr Liu discussed key efficacy and safety findings from the phase 2 VISION trial (NCT02864992) that led to the FDA approval of tepotinib for this indication; the comparable response rates seen between tissue and liquid biopsy results, as well as across NSCLC treatment lines; and the importance of early biomarker testing, including RNA sequencing, to identify actionable mutations and optimize treatment.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
